stockrowCelldex Therapeutics, Inc.
CLDX Healthcare Biotechnology
Celldex Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, down 78.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −10.6%
- Free cash flow
- −35.5%
Quarter to June 2026, against a year earlier
Follow CLDX
Alert me
Celldex Therapeutics, Inc. (CLDX) Total debt
Celldex Therapeutics, Inc.'s total debt at the end of fiscal 2025 was $1.2M, up 30.6% from $942.0K in fiscal 2024. At the end of the quarter to 30 June 2026 it was $1.2M. Over the past ten years it has ranged from $942.0K (fiscal 2024) to $6.6M (fiscal 2017); the current reading is higher than 20% of that period. Celldex Therapeutics, Inc. ranks 377th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $1.2M | 30.57% |
| FY2024 | $942.0K | (76.38%) |
| FY2023 | $4.0M | 175.99% |
| FY2022 | $1.4M | (52.50%) |
| FY2021 | $3.0M | (12.61%) |
| FY2020 | $3.5M | (4.81%) |
| FY2019 | $3.7M | (19.20%) |
| FY2018 | $4.5M | (31.07%) |
| FY2017 | $6.6M | 36.05% |
| FY2016 | $4.8M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $1.2M | 0.00% |
| Dec 2025 | $1.2M | 30.57% |
| Dec 2024 | $942.0K | (76.38%) |
| Dec 2023 | $4.0M | (5.77%) |
| 34 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| BHVN Biohaven Ltd. compare | $264.3M |
| ADMA ADMA Biologics Inc compare | $198.9M |
| VCEL Vericel Corporation compare | $85.1M |
| VERA Vera Therapeutics, Inc. compare | $75.2M |
| AUPH Aurinia Pharmaceuticals Inc compare | $39.0M |
| PVLA Palvella Therapeutics, Inc. compare | $12.3M |
| CLDX Celldex Therapeutics, Inc. | $1.2M |
| PHVS Pharvaris N.V. compare | $559.6K |
| IMNM Immunome, Inc. compare | $228.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on CLDX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement